Extrapulmonary Mycobacterium abscessus Infections, France, 2012-20201
Benoît Heid-Picard,Faiza Mougari,Anne Pouvaret,Fanny Lanternier,Zeina Awad,Emmanuelle Bille,Olivier Lortholary,Emmanuelle Cambau,Mabsc Study Group,M Cihanek,C Andrejak,H Cordel,R Barruet,C Chirouze,A Lesueur,V Castaigns,M C Receveur,A L Roux,A Desdoits,S Deshayes,A Laquievre,E Beillard,L Epelboin,M E Chanard,C Bernard,C Ragot,V Grobost,M Vidal,W Vindrios,J Bador,C Etienne,J Claudeon,E Curlier,U Françoise,S Guyomard,K Pailla,E Rossigneux,M Gueye,B Hillion,N Allou,O Belmonte,B Kuli,R Manaquin,L Raffray,M Verduyn,N Crochette,V Vieillefond,A F Georgel,P Miailhes,C Pariset,M M Ponsoda,E Pricaz,A Sénéchal,G Singier,L Delapierre,H Pegliasco,O Grossi,G Foulon,N Ehret,J M Turmel,K Risso,I Bourlaud,P Lureau,J Colot,C Bernigaud,S Bulifon,J Bustamente,A Canellas,E Caumes,S Chelabi,A Contejean,F Defournie,V Delcey,L Escaut,R Gueneau,M Humbert,V Lalande,J Lourtet,O Paccoud,J Pastre,G Simonneau,C Verdet,N Veziris,V Zeller,F Chaix,D Minette,V Fabre,I Michelet,M Lagrange,H Tchero,P Boyer,E Catherinot,I Marroun,E Oehler,K Delavigne,M Gauthier,G Dewulf,M Amara,X Brickley,A Greder Belan,M Groh,J Vendroux,E Giroudon,E Chachaty,E Gallois,F Griscelli
DOI: https://doi.org/10.3201/eid3011.240459
Abstract:Mycobacterium abscessus infection is challenging to treat. Extrapulmonary M. abscessus infections (EP-MAB) are less common than pulmonary M. abscessus infections. To evaluate treatment regimens, we retrospectively analyzed consecutive microbiologically confirmed EP-MAB cases diagnosed in France during 2012-2020. We studied 45 patients with EP-MAB, including 14 bone and joint infections, 10 skin and soft tissue infections, and 8 lymph node infections. Most (62%) patients had no reported immunodeficiency. In 27 patients, EP-MAB followed healthcare-associated (44%) or environmental (16%) injuries. Of the 45 isolates, 25 were subspecies abscessus, 10 bolletii, and 9 massiliense; 1 was unidentified. Cure was achieved for 36 (80%) patients who received a median antimicrobial regimen of 6 months; 22 (55%) also underwent surgery. Four patients died, and 5 were unavailable for follow-up. EP-MAB predominantly affects immunocompetent patients after an injury; outcomes are favorable. We propose a >6-month regimen of antimicrobial therapy with consideration for surgery and regular patient reassessment.